Search Results
Aug 27, 2026, 09:03 ET Your Gut Is Wrong About People More Often Than You Think -- Former FBI Agent Robin Dreeke Teaches You How to Fix It, Now on MasterClass
https://dam.masterclass.com/Share/17d6k7jh0ww73548dl28t0wne78r6g4m Credit: Courtesy of MasterClassAbout MasterClass:MasterClass is the personalized learning
More news about: MasterClass
Aug 17, 2026, 15:06 ET LODE GOLD COMMENCES METALLURGICAL DRILLING AT FREMONT GOLD MINE, MARIPOSA, CA
California with 43,000 m drilled, 10,000 underground channel samples, 14 adits and 2 shafts. Mining halted in 1942 due to the gold mining prohibition during WW II. It was mined at 10.7 g/t when price was gold was $35 per oz. PEA was completed (
More news about: Lode Gold Resources Inc
Aug 10, 2026, 12:11 ET LODE GOLD RECEIVES THREE-YEAR DRILL PERMIT AT FLAGSHIP FREMONT GOLD MINE, CALIFORNIA
California with 43,000 m drilled, 10,000 underground channel samples, 14 adits and 2 shafts. Mining halted in 1942 due to the gold mining prohibition during WW II. It was mined at 10.7 g/t when price was gold was $35 per oz. PEA was completed (
More news about: Lode Gold Resources Inc
Aug 05, 2026, 12:36 ET LODE GOLD COMPLETES FULL REPAYMENT OF FREMONT GOLD MINE PROPERTY SECURED LOAN AHEAD OF SCHEDULE
California with 43,000 m drilled, 10,000 underground channel samples, 14 adits and 2 shafts. Mining halted in 1942 due to the gold mining prohibition during WW II. It was mined at 10.7 g/t when price was gold was $35 per oz. PEA was completed (
More news about: Lode Gold Resources Inc
Jul 15, 2026, 05:56 ET Skyhawk Therapeutics gibt die Ausweitung seiner globalen zulassungsrelevanten klinischen Studie „FALCON-HD" für SKY-0515 zur Behandlung der Huntington-Krankheit auf die Vereinigten Staaten, Kanada und das Vereinigte Königreich bekannt
RNA-Zielstrukturen entwickelt, gibt bekannt, dass es weitere behördliche Genehmigungen für den Start seiner Phase-2/3-Schlüsselstudie FALCON-HD (004-ANZ und 004-WW) erhalten hat, und zwar in Form einer IND-Zulassung in den Vereinigten Staaten sowie CTA-Zulassungen in Kanada und im Vereinigten Königreich.
More news about: Skyhawk Therapeutics
Jul 14, 2026, 10:39 ET Skyhawk Therapeutics annonce l'extension aux États-Unis, au Canada et au Royaume-Uni de son essai clinique pivot mondial FALCON-HD portant sur le médicament SKY-0515 dans le traitement de la maladie de Huntington
petites molécules, annonce avoir obtenu des autorisations réglementaires supplémentaires pour lancer son essai pivot de phases 2/3 FALCON-HD (004-ANZ et 004-WW), avec l'acceptation d'une demande d'autorisation de nouveau médicament de recherche aux États-Unis et l'autorisation d'accords d'essai clinique au
More news about: Skyhawk Therapeutics
Jul 14, 2026, 10:34 ET Skyhawk Therapeutics: expansión de su ensayo clínico FALCON-HD para SKY-0515 en la enfermedad de Huntington
objetivos de ARN, anuncia que ha recibido aprobaciones regulatorias adicionales para abrir su ensayo fundamental de fase 2/3 FALCON-HD (004-ANZ y 004-WW), con aceptación de IND en Estados Unidos y aceptaciones CTA en Canadá y Reino Unido.
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:36 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to open its Phase 2/3 FALCON-HD (004-ANZ and 004-WW) pivotal trial, with an IND acceptance in the United States and CTA acceptances in each Canada and the United Kingdom.
More news about: Skyhawk Therapeutics
Jul 14, 2026, 08:17 ET Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
therapies designed to modulate RNA targets, announces it has received additional regulatory approvals to open its Phase 2/3 FALCON-HD (004-ANZ and 004-WW) pivotal trial, with an IND acceptance in the United States and CTA acceptances in each Canada and the United Kingdom.
More news about: Skyhawk Therapeutics
Jul 07, 2026, 10:00 ET SEMI and TechSearch International Release 2026 Edition of Worldwide Assembly & Test Facility Database
https://www.semi.org/en/products-services/market-data/ww-assembly-test-facility-database. For more information on the report or to subscribe, please contact the SEMI Market Intelligence Team at
More news about: SEMI
Jul 07, 2026, 10:00 ET SEMI and TechSearch International Release 2026 Edition of Worldwide Assembly & Test Facility Database
https://www.semi.org/en/products-services/market-data/ww-assembly-test-facility-database. For more information on the report or to subscribe, please contact the SEMI Market Intelligence Team at
More news about: SEMI
Jul 01, 2026, 17:28 ET Skyhawk Therapeutics publie les résultats à douze mois des sous-composantes de la cUHDRS issus de son essai clinique de phase 1/2 de SKY-0515 dans le traitement de la maladie de Huntington
ou élevée.Le recrutement pour l'étude de phases 1/2 est terminé.À propos du programme pivot de phases 2/3 FALCON-HD (004-ANZ and 004-WW) de SKY-0515 Le programme pivot FALCON-HD de SKY-0515 (
More news about: Skyhawk Therapeutics
Jul 01, 2026, 16:28 ET Skyhawk Therapeutics divulga os resultados dos subcomponentes do cUHDRS após doze meses de seu ensaio clínico de Fase 1/2 com o SKY-0515 na doença de Huntington
tratamento ativo em dose baixa ou alta.A inscrição no estudo de Fase 1/2 está concluída.Sobre o programa pivotal FALCON-HD (004-ANZ e 004-WW) de Fase 2/3 do SKY-0515 O programa pivotal do SKY-0515 FALCON-HD (
More news about: Skyhawk Therapeutics
Jul 01, 2026, 16:02 ET Skyhawk Therapeutics publica los resultados del subcomponente de la cUHDRS a los doce meses de su ensayo clínico de fase 1/2 con SKY-0515 para la enfermedad de Huntington
ya sea en una dosis baja o alta.La inscripción en el estudio de fase 1/2 finalizó.Acerca del programa pivotal FALCON-HD (004-ANZ y 004-WW) de fase 2/3 de SKY-0515 El programa pivotal FALCON-HD de SKY-0515 (
More news about: Skyhawk Therapeutics
Jul 01, 2026, 08:50 ET Skyhawk Therapeutics veröffentlicht die Ergebnisse der cUHDRS-Unterkomponenten nach zwölf Monaten aus seiner klinischen Phase-1/2-Studie mit SKY-0515 bei der Huntington-Krankheit
Rekrutierung für die Phase-1/2-Studie ist abgeschlossen.Informationen zum zulassungsrelevanten Phase-2/3-Programm FALCON-HD (004-ANZ und 004-WW) für SKY-0515 Das zulassungsrelevante Programm FALCON-HD für SKY-0515 (
More news about: Skyhawk Therapeutics
Jun 30, 2026, 12:51 ET Skyhawk Therapeutics publica los resultados de doce meses del subcomponente cUHDRS
alta.El periodo de inscripción para el estudio de fase 1/2 ha finalizado.Acerca del programa fundamental FALCON-HD (004-ANZ y 004-WW) de fase 2/3 de SKY-0515 (SKY-0515).El programa fundamental FALCON-HD de SKY-0515 (
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
treatment at either a low or high dose.Enrollment in the Phase 1/2 study is complete.About SKY-0515's Phase 2/3 FALCON-HD (004-ANZ and 004-WW) Pivotal Program SKY-0515's FALCON-HD pivotal program (
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
treatment at either a low or high dose.Enrollment in the Phase 1/2 study is complete.About SKY-0515's Phase 2/3 FALCON-HD (004-ANZ and 004-WW) Pivotal Program SKY-0515's FALCON-HD pivotal program (
More news about: Skyhawk Therapeutics
Jun 23, 2026, 08:57 ET EDB Launches Agentic Database, Converged Analytics, and Governance, Bringing Sovereign AI Where Enterprise Data Already Lives
AI-ready infrastructure foundation. Together, we enable a resilient data ecosystem that supports data sovereignty," said Unnikrishnan Rajagopal, WW director for ISV Ecosystem, GSIs and Alliances, IBM."Red Hat Ansible Automation Platform plus EDB Postgres AI delivers
More news about: EnterpriseDB
Jun 18, 2026, 13:54 ET Wendy C. Wilson Recognized for Leadership Resilience Speaking and Executive Coaching
Boundaries, and Sustainable Performance, Turning Invisible Scars into Leadership Strength, and Cultural Competence in Leadership. Her signature program, The WW Performance Edge, is designed to help leaders sustain performance under pressure and emerge stronger from challenge.Ms. Wilson's corporate career
More news about: The Inner Circle
Jun 10, 2026, 10:00 ET AT&T Launches Unlimited Day Pass, Bringing Connectivity to iPad Users Regardless of Carrier
(NA)iPad (A16) A3355iPad Pro 12.9in (6th gen) - A2764 (WW)iPad Pro 13 A2926 (2024)iPad (A16) Ch A3356iPad Air 11 A2903 (2024)iPad 9th Gen A2603 (NA)iPad (10th gen) - A2757 (WW)iPad Pro 12.9in (5th gen) A2379 (NA)iPad Mini 5G A2568
More news about: AT&T
Jun 10, 2026, 06:40 ET Subtle Medical Receives FDA Clearance for SubtleHD™(CT), Expanding AI-Powered Image Enhancement into CT Imaging
here: https://us02web.zoom.us/webinar/register/4517810361583/WN_f1Ww9jOQTmCNqdoV5ICjKQAbout Subtle Medical, Inc.Subtle Medical is a leading provider of AI-powered imaging solutions,
More news about: Subtle Medical, Inc.
Jun 09, 2026, 22:23 ET GIGABYTE présente ses performances CQDIMM exceptionnelles et le développement de son écosystème au salon COMPUTEX 2026
GIGABYTE : https://bit.ly/COMPUTEX_2026_GIGABYTE_Consumer_ww_cqdimm_ecosystemPhoto - https://mma.prnewswire.com/media/2988662/image1.jpg
More news about: GIGABYTE
Jun 03, 2026, 21:00 ET GIGABYTE、COMPUTEX 2026で業界をリードするCQDIMM性能とエコシステム拡大を紹介
ます。COMPUTEX 2026のGIGABYTEコンシューマーブース#M0520にて、CQDIMMの展示をぜひご体験ください。詳細については、GIGABYTE公式ウェブサイトをご覧ください：https://bit.ly/COMPUTEX_2026_GIGABYTE_Consumer_ww_cqdimm_ecosystem
More news about: GIGABYTE
Jun 03, 2026, 21:00 ET GIGABYTE Showcases Industry-leading CQDIMM Performance and Ecosystem Expansion at COMPUTEX 2026
website: https://bit.ly/COMPUTEX_2026_GIGABYTE_Consumer_ww_cqdimm_ecosystem
More news about: GIGABYTE